Stock vs Stock Comparison

Esperion Therapeutics, Inc. vs AbbVie Inc.

ABBV wins the Tale of the Tape 7–2.

ESPR
ABBV$215.40

🏆 Tale of the Tape

27
ESPRABBV
-5.6%Profitability (Net Margin)6.9%
Valuation (P/E)106.2x
30.5%Efficiency (ROIC)8.3%
4/9Health (Piotroski F)7/9
Safety (Altman Z)2.0
21.3%Growth (Rev YoY)8.6%
Risk (Sharpe 1Y)0.61
-2.54xBalance Sheet (D/E)-42.50x
FCF Yield4.23%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Fundamentals

MetricESPRABBV
Market Cap$384.7B
P/E Ratio106.2x
Forward P/E13.4x
P/B-57.80x
Dividend Yield3.18%
Beta0.30

Quantitative Metrics

MetricESPRABBV
DCF Fair Value$126.26
DCF Upside-38.9%
Piotroski F4/97/9
Altman Z2.01
Beneish M-1.97-2.87
FCF Yield4.23%
Net Debt/EBITDA1.3x3.0x
ROIC30.5%8.3%
WACC7.4%
ROIC – WACC0.8pp
Gross Margin68.0%70.2%
Net Margin-5.6%6.9%
Rev Growth YoY21.3%8.6%
Sharpe (1Y)0.61
Max Drawdown 3Y
FCF Payout Ratio65%

ESPR Price

Loading chart...

ABBV Price

Loading chart...

ETF Exposure

ESPR found in:

XPH2.12%
VFMO0.09%
VHT0.01%

ABBV found in:

XLV7.07%
IYH6.86%
VHT6.04%
HDV5.61%
SCHD3.53%
DGRO2.52%
DGRW1.99%
MGV1.85%
VIG1.68%
VYM1.56%
NOBL1.49%
VTV1.46%
SDY1.42%
IWF1.39%
SCHV1.38%
VONG1.21%
XBI1.09%
ESGV0.78%
SPYV0.71%
IVV0.69%
SPLG0.68%
SCHX0.66%
SCHB0.62%
ITOT0.61%
VOO0.60%
SPY0.59%
VONE0.57%
SPTM0.55%
VTI0.54%
SPYG0.50%
URTH0.48%
ACWI0.41%
VFVA0.41%
VT0.33%
QUS0.32%
VFMV0.25%
RSP0.19%
ONEO0.03%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

ESPR vs ABBV: Head-to-Head Analysis

Esperion Therapeutics, Inc. (ESPR) and AbbVie Inc. (ABBV) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, ABBV leads 7–2 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, ESPR generates a return on invested capital (ROIC) of 30.5% compared to ABBV's 8.3%. This suggests ESPR is more effective at deploying capital to generate shareholder returns.

ESPR appears in 3 ETFs tracked by SecuritiesDB, while ABBV appears in 38 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, ESPR or ABBV?

Our quantitative analysis compares ESPR and ABBV across nine fundamental dimensions. ABBV wins the Tale of the Tape 7–2. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are ESPR and ABBV correlated?

Correlation data is not yet available for this pair. Check back after both stocks have sufficient trading history.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.